NHT
ABBV icon

New Hampshire Trust’s AbbVie ABBV Stock Holding History

New Hampshire Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.4M Sell
34,033
-195
-0.6% -$43.3K 1.49% 17
2025
Q4 		$7.82M Sell
34,228
-2,441
-7% -$556K 1.52% 13
2025
Q3 		$8.49M Buy
36,669
+658
+2% +$134K 1.64% 14
2025
Q2 		$6.68M Buy
36,011
+763
+2% +$142K 1.4% 14
2025
Q1 		$7.39M Sell
35,248
-966
-3% -$188K 1.69% 12
2024
Q4 		$6.44M Buy
36,214
+99
+0.3% +$18.2K 1.36% 14
2024
Q3 		$7.13M Sell
36,115
-200
-0.6% -$37.3K 1.53% 13
2024
Q2 		$6.23M Sell
36,315
-42
-0.1% -$6.96K 1.42% 14
2024
Q1 		$6.62M Buy
36,357
+1,092
+3% +$188K 1.55% 12
2023
Q4 		$5.47M Sell
35,265
-945
-3% -$138K 1.31% 17
2023
Q3 		$5.4M Sell
36,210
-1,079
-3% -$158K 1.47% 15
2023
Q2 		$5.02M Buy
37,289
+143
+0.4% +$21K 1.31% 18
2023
Q1 		$5.92M Sell
37,146
-1,382
-4% -$211K 1.59% 11
2022
Q4 		$6.23M Buy
+38,528
New +$5.91M 1.65% 10

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

New Hampshire Trust's ABBV Position: Q1 2026 in Review

New Hampshire Trust reduced its AbbVie (ABBV) stake by 0.57% in Q1 2026, selling an estimated $43.3K and leaving 34,033 shares worth $7.4M. The position accounts for 1.49% of the portfolio, ranked #17.

New Hampshire Trust first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.49M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • New Hampshire Trust held 34,033 shares of AbbVie worth $7.4M as of Q1 2026.
  • New Hampshire Trust sold 195 AbbVie shares in Q1 2026, an estimated $43.3K.
  • AbbVie made up 1.49% of New Hampshire Trust's portfolio in Q1 2026, its #17 holding.
  • New Hampshire Trust first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • New Hampshire Trust's AbbVie position peaked at $8.49M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on New Hampshire Trust's 13F filing for Q1 2026, filed 20 Apr 2026.